CYTL1 and breast cancer: Because DNA hypermethylation may account for the low expression of CYTL1 in breast cancer,11 we evaluated the effect of the DNA-demethylating agent decitabine on CYTL1 expression in the MDA-MB-231 breast cancer cell line.13 Decitabine increased the mRNA expression of CYTL1 in a time-dependent manner (Supplementary Fig. S2a).